XML 31 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Segments
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segments Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the Chief Operating Decision Maker (“CODM”) or decision-making group in making decisions on how to allocate resources and assess performance. The Company’s CODM is its CEO. The CEO views the Company’s operations and manages the Company’s business as one operating segment, which is the business of developing and commercializing genome editing technology.
The Company’s CEO manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with our long-term company-wide strategic goals. In making these decisions, the Company’s CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on the Company’s consolidated net loss. Through this analysis, the CODM assesses performance by comparing actual consolidated net loss versus the budget, and then decides how to allocate resources to invest in the Company’s research and development programs. The measure of segment assets is reported on the consolidated balance sheet as total assets.
The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Collaboration and other research and development revenues$7,543 $61 $15,779 $1,710 
Operating expenses:
Research and development1
Employee related expenses6,468 14,486 29,210 41,830 
External research and development expenses6,465 20,058 66,930 64,670 
Facility expenses3,254 7,229 17,228 19,818 
Stock-based compensation expenses634 2,048 2,404 7,081 
Sublicense and license fees1,292 307 1,404 7,060 
Other expenses2
1,662 3,511 9,447 10,177 
General and administrative3
Employee related expenses2,491 5,902 11,033 15,594 
Professional service expenses1,902 4,121 7,262 10,929 
Intellectual property and patent related fees5,279 3,291 11,836 11,080 
Stock-based compensation expenses1,594 2,754 5,467 10,316 
Facility and other expenses4
1,050 2,020 5,813 7,714 
Total operating expenses32,091 65,727 168,034 206,269 
Operating loss(24,548)(65,666)(152,255)(204,559)
Other (expense) income, net:
Interest expense related to sale of future revenues(2,399)— (6,635)— 
Interest income, net1,831 3,530 6,634 12,861 
Other expense, net(1)(5)(2,184)— 
Total other (expense) income, net(569)3,525 (2,185)12,861 
Net loss$(25,117)$(62,141)$(154,440)$(191,698)
1 The nine months ended September 30, 2025 include $64,075 of restructuring and impairment charges. The three months ended September 30, 2025 and the three and nine months ended September 30, 2024 include no restructuring and impairment charges, respectively.
2 Other expenses primarily consists of impairment charges, consultant fees and office expenses.
3 The nine months ended September 30, 2025 include $2,860 of restructuring and impairment charges. The three months ended September 30, 2025 and the three and nine months ended September 30, 2024 include no restructuring and impairment charges, respectively.
4 Facility and other expenses primarily consists of rent expense, insurance premiums, depreciation expense, software licenses and office expenses.